{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:02:54Z","timestamp":1790996574401,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20220818102206014"],"award-info":[{"award-number":["JCYJ20220818102206014"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bbr.2024.115410","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T18:57:11Z","timestamp":1735239431000},"page":"115410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Effects of MAO\u2011B inhibitors in life quality of Parkinson\u2019s disease patients: A systematic review and meta\u2011analysis"],"prefix":"10.1016","volume":"480","author":[{"given":"Xiaohuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiehua","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonggui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2024.115410_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fnagi.2019.00372","article-title":"Emerging role of sirtuin 2 in Parkinson's disease","volume":"11","author":"Liu","year":"2019","journal-title":"Front Aging Neurosci."},{"issue":"5674","key":"10.1016\/j.bbr.2024.115410_bib2","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1126\/science.1098966","article-title":"Biomedicine. Parkinson's--divergent causes, convergent mechanisms","volume":"304","author":"Greenamyre","year":"2004","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bbr.2024.115410_bib3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2165\/00002512-200623090-00001","article-title":"A review of the health-related quality of life and economic impact of Parkinson's disease","volume":"23","author":"Dowding","year":"2006","journal-title":"Drugs Aging"},{"issue":"8","key":"10.1016\/j.bbr.2024.115410_bib4","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s10072-018-3423-1","article-title":"Romberg ratio coefficient in quiet stance and postural control in Parkinson's disease","volume":"39","author":"Paolucci","year":"2018","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.bbr.2024.115410_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-0404.2010.01344.x","article-title":"Activities of daily living and quality of life in persons with newly diagnosed Parkinson's disease according to subtype of disease, and in comparison to healthy controls","volume":"123","author":"Hariz","year":"2011","journal-title":"Acta Neurol. Scand."},{"issue":"5","key":"10.1016\/j.bbr.2024.115410_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/ane.12760","article-title":"Non-motor symptoms and quality of life in subjects with mild parkinsonian signs","volume":"136","author":"Prasuhn","year":"2017","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.bbr.2024.115410_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/cns.13549","article-title":"Quality of life in Parkinson's disease: a systematic review and meta-analysis of comparative studies","volume":"27","author":"Zhao","year":"2021","journal-title":"CNS Neurosci. Ther."},{"issue":"5","key":"10.1016\/j.bbr.2024.115410_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"18","year":"2019","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.bbr.2024.115410_bib9","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2024.115410_bib10","first-page":"229","article-title":"Levodopa in the treatment of Parkinson's disease: an old drug still going strong","volume":"5","author":"Poewe","year":"2010","journal-title":"Clin. Inter. Aging"},{"issue":"1","key":"10.1016\/j.bbr.2024.115410_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000215875","article-title":"Levodopa: past, present, and future","volume":"62","author":"Hauser","year":"2009","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.bbr.2024.115410_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40035-016-0059-z","article-title":"The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease","volume":"5","author":"Chen","year":"2016","journal-title":"Transl. Neurodegener."},{"issue":"9","key":"10.1016\/j.bbr.2024.115410_bib13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/1570159X16666180830100754","article-title":"Different generations of Type-B monoamine oxidase inhibitors in Parkinson's disease: from bench to bedside","volume":"17","author":"Alborghetti","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bbr.2024.115410_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108024","article-title":"Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease","volume":"170","author":"Sciaccaluga","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2024.115410_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41531-022-00339-2","article-title":"Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's disease: a systematic review","volume":"8","author":"Tsuboi","year":"2022","journal-title":"NPJ Park. Dis."},{"issue":"11","key":"10.1016\/j.bbr.2024.115410_bib16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40263-023-01048-x","article-title":"Efficacy and Safety of MAO-B inhibitors safinamide and zonisamide in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Aboulatta","year":"2023","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.bbr.2024.115410_bib17","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"issue":"7454","key":"10.1016\/j.bbr.2024.115410_bib18","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"Bmj"},{"key":"10.1016\/j.bbr.2024.115410_bib19","unstructured":"Higgins JPT, G.Se, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011."},{"key":"10.1016\/j.bbr.2024.115410_bib20","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"10.1016\/j.bbr.2024.115410_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40035-018-0119-7","article-title":"Adjunct rasagiline to treat Parkinson's disease with motor fluctuations: a randomized, double-blind study in China","volume":"7","author":"Zhang","year":"2018","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.bbr.2024.115410_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40035-018-0137-5","article-title":"Efficacy and safety of rasagiline in Chinese patients with early Parkinson's disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study","volume":"7","author":"Zhang","year":"2018","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.bbr.2024.115410_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.parkreldis.2018.04.025","article-title":"Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2\/3, randomized, double-blind, placebo-controlled, multicenter study","volume":"53","author":"Hattori","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.bbr.2024.115410_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.parkreldis.2018.08.024","article-title":"Rasagiline monotherapy in early Parkinson's disease: a phase 3, randomized study in Japan","volume":"60","author":"Hattori","year":"2019","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.bbr.2024.115410_bib25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00702-018-1964-3","article-title":"Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease","volume":"126","author":"Hattori","year":"2019","journal-title":"J. Neural Transm."},{"issue":"5","key":"10.1016\/j.bbr.2024.115410_bib26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/mds.20764","article-title":"Rasagiline improves quality of life in patients with early Parkinson's disease","volume":"21","author":"Biglan","year":"2006","journal-title":"Mov. Disord."},{"issue":"13","key":"10.1016\/j.bbr.2024.115410_bib27","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/mds.26429","article-title":"Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease","volume":"30","author":"Lim","year":"2015","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.bbr.2024.115410_bib28","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mds.25877","article-title":"Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease","volume":"29","author":"Hauser","year":"2014","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.bbr.2024.115410_bib29","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/ene.12724","article-title":"A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients","volume":"22","author":"Barone","year":"2015","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.bbr.2024.115410_bib30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/ene.13567","article-title":"Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial","volume":"25","author":"Schrempf","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.bbr.2024.115410_bib31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients With Parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Schapira","year":"2017","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.bbr.2024.115410_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.bbr.2024.115410_bib33","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","article-title":"Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2024.115410_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","article-title":"Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: a randomized, double-blind, placebo-controlled, phase II\/III study","volume":"75","author":"Hattori","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"11","key":"10.1016\/j.bbr.2024.115410_bib35","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s40263-022-00958-6","article-title":"The XINDI study: a randomized phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in chinese patients with Parkinson's disease with motor fluctuations","volume":"36","author":"Wei","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2024.115410_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.866502","article-title":"A randomized clinical trial to evaluate the effects of safinamide on apathetic non-demented patients with Parkinson's disease","volume":"13","author":"Kulisevsky","year":"2022","journal-title":"Front Neurol."},{"issue":"11","key":"10.1016\/j.bbr.2024.115410_bib37","doi-asserted-by":"crossref","first-page":"880","DOI":"10.4088\/JCP.v61n1113","article-title":"Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients","volume":"61","author":"Ritsner","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2024.115410_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jocn.2018.06.013","article-title":"Quality of life and Parkinson's disease: Philippine translation and validation of the Parkinson's disease questionnaire","volume":"54","author":"Suratos","year":"2018","journal-title":"J. Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.bbr.2024.115410_bib39","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/1531-8257(200011)15:6<1112::AID-MDS1008>3.0.CO;2-A","article-title":"How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population","volume":"15","author":"Schrag","year":"2000","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.bbr.2024.115410_bib40","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.apmr.2016.05.020","article-title":"Use of the world health organization quality of life assessment short version in mild to moderate Parkinson disease","volume":"97","author":"Hendred","year":"2016","journal-title":"Arch. Phys. Med Rehabil."},{"issue":"10","key":"10.1016\/j.bbr.2024.115410_bib41","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/mds.21408","article-title":"Determinants of quality of life in Brazilian patients with Parkinson's disease","volume":"22","author":"Carod-Artal","year":"2007","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.bbr.2024.115410_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2517","article-title":"The quality of life in patients with Parkinson's disease: focus on gender difference","volume":"12","author":"Meng","year":"2022","journal-title":"Brain Behav."},{"issue":"1","key":"10.1016\/j.bbr.2024.115410_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.26719\/emhj.23.013","article-title":"Systematic review and meta-analysis of the quality-of-life of patients with Parkinson's disease","volume":"29","author":"Hoseinipalangi","year":"2023","journal-title":"East Mediterr. Health J."},{"issue":"4","key":"10.1016\/j.bbr.2024.115410_bib44","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3138\/ptc.2011-26","article-title":"Health-related quality of life of Australians with Parkinson disease: a comparison with international studies","volume":"64","author":"Soh","year":"2012","journal-title":"Physiother. Can."},{"issue":"2","key":"10.1016\/j.bbr.2024.115410_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/0028-3886.79133","article-title":"Relationship of depression, disability, and quality of life in Parkinson's disease: a hospital-based case-control study","volume":"59","author":"Arun","year":"2011","journal-title":"Neurol. India"},{"issue":"6","key":"10.1016\/j.bbr.2024.115410_bib46","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/mds.24999","article-title":"Depression and quality of life in monogenic compared to idiopathic, early-onset Parkinson's disease","volume":"27","author":"Kasten","year":"2012","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.bbr.2024.115410_bib47","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joor.13304","article-title":"Oral health-related quality of life in patients with Parkinson's disease","volume":"49","author":"Verhoeff","year":"2022","journal-title":"J. Oral. Rehabil."},{"key":"10.1016\/j.bbr.2024.115410_bib48","doi-asserted-by":"crossref","first-page":"1035721","DOI":"10.3389\/fneur.2022.1035721","article-title":"Quality of life: seasonal fluctuation in Parkinson's disease","volume":"13","author":"Wu","year":"2022","journal-title":"Front Neurol."},{"issue":"2","key":"10.1016\/j.bbr.2024.115410_bib49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/jamaneurol.2017.3517","article-title":"Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo parkinson disease: a phase 2 randomized clinical trial","volume":"75","author":"Schenkman","year":"2018","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.bbr.2024.115410_bib50","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(19)30285-6","article-title":"Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial","volume":"18","author":"van der Kolk","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbr.2024.115410_bib51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ctcp.2019.04.005","article-title":"Effects of dance therapy on cognitive and mood symptoms in people with Parkinson's disease: a systematic review and meta-analysis","volume":"36","author":"Zhang","year":"2019","journal-title":"Complement Ther. Clin. Pr."},{"issue":"7","key":"10.1016\/j.bbr.2024.115410_bib52","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaneurol.2019.0534","article-title":"Effects of mindfulness yoga vs stretching and resistance training exercises on anxiety and depression for people with parkinson disease: a randomized clinical trial","volume":"76","author":"Kwok","year":"2019","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.bbr.2024.115410_bib53","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s00415-018-8761-7","article-title":"Patient-centered integrated healthcare improves quality of life in Parkinson's disease patients: a randomized controlled trial","volume":"265","author":"Eggers","year":"2018","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.bbr.2024.115410_bib54","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10072-018-3628-3","article-title":"Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease","volume":"40","author":"Bianchi","year":"2019","journal-title":"Neurol. Sci."},{"issue":"4","key":"10.1016\/j.bbr.2024.115410_bib55","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12325-018-0687-z","article-title":"Long-term efficacy of safinamide on Parkinson's disease chronic pain","volume":"35","author":"Cattaneo","year":"2018","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.bbr.2024.115410_bib56","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.parkreldis.2014.04.020","article-title":"Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients","volume":"20","author":"Brusa","year":"2014","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.bbr.2024.115410_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0304-3959(94)00172-B","article-title":"The role of the basal ganglia in nociception and pain","volume":"60","author":"Chudler","year":"1995","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.bbr.2024.115410_bib58","first-page":"629","article-title":"Long-term effects of safinamide on mood fluctuations in Parkinson's disease","volume":"7","author":"Cattaneo","year":"2017","journal-title":"J. Park. Dis."},{"issue":"9","key":"10.1016\/j.bbr.2024.115410_bib59","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1468-1331.2010.02986.x","article-title":"Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease","volume":"17","author":"Reichmann","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.bbr.2024.115410_bib60","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/mds.26235","article-title":"The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study","volume":"30","author":"Hanagasi","year":"2015","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.bbr.2024.115410_bib61","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/mds.26617","article-title":"Rasagiline for mild cognitive impairment in Parkinson's disease: a placebo-controlled trial","volume":"31","author":"Weintraub","year":"2016","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.bbr.2024.115410_bib62","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00702-020-02259-y","article-title":"Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study","volume":"128","author":"Rinaldi","year":"2021","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"24","key":"10.1016\/j.bbr.2024.115410_bib63","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3109\/09638288.2014.886727","article-title":"The role of social support in anxiety and depression among Parkinson's disease patients","volume":"36","author":"Ghorbani Saeedian","year":"2014","journal-title":"Disabil. Rehabil."},{"issue":"12","key":"10.1016\/j.bbr.2024.115410_bib64","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00702-022-02558-6","article-title":"Perceived social support declines after deep brain stimulation surgery in patients with Parkinson's disease","volume":"129","author":"Spagna","year":"2022","journal-title":"J. Neural Transm. (Vienna)"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432824005667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432824005667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T02:51:06Z","timestamp":1739155866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432824005667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":64,"alternative-id":["S0166432824005667"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2024.115410","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of MAO\u2011B inhibitors in life quality of Parkinson\u2019s disease patients: A systematic review and meta\u2011analysis","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2024.115410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115410"}}